A comprehensive review of retinal gene therapy

Molecular Therapy

Volumn 21, Issue 3, 2013, Pages 509-519

  Boye, Shannon E ^a,b   Boye, Sanford L ^a,b   Lewin, Alfred S ^b   Hauswirth, William W ^a,b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; ADENOVIRUS VECTOR; ANGIOSTATIN; ATP BINDING CASSETTE A4; CHAPERONE; CYCLIC NUCLEOTIDE GATED CHANNEL; CYCLIC NUCLEOTIDE GATED CHANNEL ALPHA 3; CYCLIC NUCLEOTIDE GATED CHANNEL BETA 3; ENDOSTATIN; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GUANYLATE CYCLASE; GUANYLATE CYCLASE 1; HELICASE; LENTIVIRUS VECTOR; MER RECEPTOR TYROSINE KINASE; MYOSIN VIIA; NADH DEHYDROGENASE SUBUNIT 4; PARVOVIRUS VECTOR; RAB ESCORT PROTEIN 1; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE; RETINAL PIGMENT EPITHELIUM SPECIFIC 65 KDA PROTEIN; RETINOSCHISIN; SOLUBLE VASCULOTROPIN RECEPTOR 1; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 1; VISUAL PIGMENT;

ABSENCE OF SIDE EFFECTS; ANTIANGIOGENIC ACTIVITY; ANTIOXIDANT ACTIVITY; ATP BINDING CASSETTE A4 GENE; AUTOSOMAL DOMINANT RETINITIS PIGMENTOSA; AUTOSOMAL RECESSIVE RETINITIS PIGMENTOSA; CHOROIDEREMIA; CLINICAL TRIAL (TOPIC); COLOR BLINDNESS; CYCLIC NUCLEOTIDE GATED CHANNEL ALPHA 3 GENE; CYCLIC NUCLEOTIDE GATED CHANNEL BETA 3 GENE; DRUG EFFICACY; DRUG SAFETY; EXUDATIVE MACULAR DEGENERATION; EYE FIXATION; GENE; GENE EXPRESSION; GENE MUTATION; GENE REPLACEMENT THERAPY; GENE THERAPY; GENETIC TRANSDUCTION; GUANYLATE CYCLASE 1 GENE; HUMAN; IMMUNOTOXICITY; LEBER CONGENITAL AMAUROSIS; LEBER HEREDITARY OPTIC NEUROPATHY; MER RECEPTOR TYROSINE KINASE GENE; MYOSIN VIIA GENE; NADH DEHYDROGENASE SUBUNIT 4 GENE; NEUROPROTECTION; NONHUMAN; PATHOGENESIS; RAB ESCORT PROTEIN 1 GENE; RETINA DEGENERATION; RETINA DISEASE; RETINAL PIGMENT EPITHELIUM SPECIFIC 65 KDA PROTEIN GENE; RETINITIS PIGMENTOSA; RETINOSCHISIN GENE; RETINOSCHISIS; REVIEW; SOLUBLE VASCULOTROPIN RECEPTOR 1 GENE; STARGARDT DISEASE; USHER SYNDROME; VIRAL GENE THERAPY; VISUAL ACUITY; VISUAL IMPAIRMENT;

ANIMALIA;

EID: 84875220318     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2012.280     Document Type: Review

References (208)

1. Rodieck, RW (1998). The First Steps in Seeing. Sinauer Associates: Sunderland.
2. Jin, M, Li, S, Moghrabi, WN, Sun, H and Travis, GH (2005). Rpe65 is the retinoid isomerase in bovine retinal pigment epithelium. Cell 122: 449-459.
3. Moiseyev, G, Chen, Y, Takahashi, Y, Wu, BX and Ma, JX (2005). RPE65 is the isomerohydrolase in the retinoid visual cycle. Proc Natl Acad Sci USA 102: 12413-12418.
4. Redmond, TM, Poliakov, E, Yu, S, Tsai, JY, Lu, Z and Gentleman, S (2005). Mutation of key residues of RPE65 abolishes its enzymatic role as isomerohydrolase in the visual cycle. Proc Natl Acad Sci USA 102: 13658-13663.
5. Cideciyan, AV (2010). Leber congenital amaurosis due to RPE65 mutations and its treatment with gene therapy. Prog Retin Eye Res 29: 398-427.
6. Acland, GM, Aguirre, GD, Ray, J, Zhang, Q, Aleman, TS, Cideciyan, AV et al. (2001). Gene therapy restores vision in a canine model of childhood blindness. Nat Genet 28: 92-95.
7. Narfström, K, Katz, ML, Bragadottir, R, Seeliger, M, Boulanger, A, Redmond, TM et al. (2003). Functional and structural recovery of the retina after gene therapy in the RPE65 null mutation dog. Invest Ophthalmol Vis Sci 44: 1663-1672.
8. Acland, GM, Aguirre, GD, Bennett, J, Aleman, TS, Cideciyan, AV, Bennicelli, J et al. (2005). Long-term restoration of rod and cone vision by single dose rAAV-mediated gene transfer to the retina in a canine model of childhood blindness. Mol Ther 12: 1072-1082.
9. Narfström, K, Vaegan, Katz, M, Bragadottir, R, Rakoczy, EP and Seeliger, M (2005). Assessment of structure and function over a 3-year period after gene transfer in RPE65-/- dogs. Doc Ophthalmol 111: 39-48.
10. Jacobson, SG, Acland, GM, Aguirre, GD, Aleman, TS, Schwartz, SB, Cideciyan, AV et al. (2006). Safety of recombinant adeno-associated virus type 2-RPE65 vector delivered by ocular subretinal injection. Mol Ther 13: 1074-1084.
11. Le Meur, G, Stieger, K, Smith, AJ, Weber, M, Deschamps, JY, Nivard, D et al. (2007). Restoration of vision in RPE65-deficient Briard dogs using an AAV serotype 4 vector that specifically targets the retinal pigmented epithelium. Gene Ther 14: 292-303.
12. Bennicelli, J, Wright, JF, Komaromy, A, Jacobs, JB, Hauck, B, Zelenaia, O et al. (2008). Reversal of blindness in animal models of leber congenital amaurosis using optimized AAV2-mediated gene transfer. Mol Ther 16: 458-465.
13. Narfström, K, Seeliger, M, Lai, CM, Vaegan, Katz, M, Rakoczy, EP et al. (2008). Morphological aspects related to long-term functional improvement of the retina in the 4 years following rAAV-mediated gene transfer in the RPE65 null mutation dog. Adv Exp Med Biol 613: 139-146.
14. Aguirre, GK, Komáromy, AM, Cideciyan, AV, Brainard, DH, Aleman, TS, Roman, AJ et al. (2007). Canine and human visual cortex intact and responsive despite early retinal blindness from RPE65 mutation. PLoS Med 4: e230.
15. Redmond, TM, Yu, S, Lee, E, Bok, D, Hamasaki, D, Chen, N et al. (1998). Rpe65 is necessary for production of 11-cis-vitamin A in the retinal visual cycle. Nat Genet 20: 344-351.
16. Dejneka, NS, Surace, EM, Aleman, TS, Cideciyan, AV, Lyubarsky, A, Savchenko, A et al. (2004). In utero gene therapy rescues vision in a murine model of congenital blindness. Mol Ther 9: 182-188.
17. Jacobson, SG, Aleman, TS, Cideciyan, AV, Sumaroka, A, Schwartz, SB, Windsor, EA et al. (2005). Identifying photoreceptors in blind eyes caused by RPE65 mutations: Prerequisite for human gene therapy success. Proc Natl Acad Sci USA 102: 6177-6182.
18. Chen, Y, Moiseyev, G, Takahashi, Y and Ma, JX (2006). RPE65 gene delivery restores isomerohydrolase activity and prevents early cone loss in Rpe65-/- mice. Invest Ophthalmol Vis Sci 47: 1177-1184.
19. Pang, JJ, Chang, B, Hawes, NL, Hurd, RE, Davisson, MT, Li, J et al. (2005). Retinal degeneration 12 (rd12): a new, spontaneously arising mouse model for human Leber congenital amaurosis (LCA). Mol Vis 11: 152-162.
20. Pang, JJ, Chang, B, Kumar, A, Nusinowitz, S, Noorwez, SM, Li, J et al. (2006). Gene therapy restores vision-dependent behavior as well as retinal structure and function in a mouse model of RPE65 Leber congenital amaurosis. Mol Ther 13: 565-572.
21. Roman, AJ, Boye, SL, Aleman, TS, Pang, JJ, McDowell, JH, Boye, SE et al. (2007). Electroretinographic analyses of Rpe65-mutant rd12 mice: developing an in vivo bioassay for human gene therapy trials of Leber congenital amaurosis. Mol Vis 13: 1701-1710.
22. Cideciyan, AV, Aleman, TS, Boye, SL, Schwartz, SB, Kaushal, S, Roman, AJ et al. (2008). Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics. Proc Natl Acad Sci USA 105: 15112-15117.
23. Banin, E, Bandah-Rozenfeld, D, Obolensky, A, Cideciyan, AV, Aleman, TS, Marks- Ohana, D et al. (2010). Molecular anthropology meets genetic medicine to treat blindness in the North African Jewish population: human gene therapy initiated in Israel. Hum Gene Ther 21: 1749-1757.
24. Wang, JS, Estevez, ME, Cornwall, MC and Kefalov, VJ (2009). Intra-retinal visual cycle required for rapid and complete cone dark adaptation. Nat Neurosci 12: 295-302.
25. Wang, JS and Kefalov, VJ (2009). An alternative pathway mediates the mouse and human cone visual cycle. Curr Biol 19: 1665-1669.
26. Jacobson, SG, Aleman, TS, Cideciyan, AV, Heon, E, Golczak, M, Beltran, WA et al. (2007). Human cone photoreceptor dependence on RPE65 isomerase. Proc Natl Acad Sci USA 104: 15123-15128.
27. Bemelmans, AP, Kostic, C, Hornfeld, D, Jaquet, M, Crippa, SV, Hauswirth, WW et al. (2006). Lentiviral vectors containing a retinal pigment epithelium specific promoter for leber congenital amaurosis gene therapy. Lentiviral gene therapy for LCA. Adv Exp Med Biol 572: 247-253.
28. Bemelmans, AP, Kostic, C, Crippa, SV, Hauswirth, WW, Lem, J, Munier, FL et al. (2006). Lentiviral gene transfer of RPE65 rescues survival and function of cones in a mouse model of Leber congenital amaurosis. PLoS Med 3: e347.
29. Pang, J, Boye, SE, Lei, B, Boye, SL, Everhart, D, Ryals, R et al. (2010). Selfcomplementary AAV-mediated gene therapy restores cone function and prevents cone degeneration in two models of Rpe65 deficiency. Gene Ther 17: 815-826.
30. Narfström, K, Katz, ML, Ford, M, Redmond, TM, Rakoczy, E and Bragadóttir, R (2003). in vivo gene therapy in young and adult RPE65-/- dogs produces long-term visual improvement. J Hered 94: 31-37.
31. Li, X, Li, W, Dai, X, Kong, F, Zheng, Q, Zhou, X et al. (2011). Gene therapy rescues cone structure and function in the 3-month-old rd12 mouse: a model for midcourse RPE65 leber congenital amaurosis. Invest Ophthalmol Vis Sci 52: 7-15.
32. Maguire, AM, Simonelli, F, Pierce, EA, Pugh, EN Jr, Mingozzi, F, Bennicelli, J et al. (2008). Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med 358: 2240-2248.
33. Bainbridge, JW, Smith, AJ, Barker, SS, Robbie, S, Henderson, R, Balaggan, K et al. (2008). Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med 358: 2231-2239.
34. Hauswirth, WW, Aleman, TS, Kaushal, S, Cideciyan, AV, Schwartz, SB, Wang, L et al. (2008). Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial. Hum Gene Ther 19: 979-990.
35. Cideciyan, AV, Hauswirth, WW, Aleman, TS, Kaushal, S, Schwartz, SB, Boye, SL et al. (2009). Human RPE65 gene therapy for Leber congenital amaurosis: persistence of early visual improvements and safety at 1 year. Hum Gene Ther 20: 999-1004.
36. Cideciyan, AV, Hauswirth, WW, Aleman, TS, Kaushal, S, Schwartz, SB, Boye, SL et al. (2009). Vision 1 year after gene therapy for Leber's congenital amaurosis. N Engl J Med 361: 725-727.
37. Maguire, AM, High, KA, Auricchio, A, Wright, JF, Pierce, EA, Testa, F et al. (2009). Agedependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial. Lancet 374: 1597-1605.
38. Simonelli, F, Maguire, AM, Testa, F, Pierce, EA, Mingozzi, F, Bennicelli, JL et al. (2010). Gene therapy for Leber's congenital amaurosis is safe and effective through 1.5 years after vector administration. Mol Ther 18: 643-650.
39. Jacobson, SG, Cideciyan, AV, Ratnakaram, R, Heon, E, Schwartz, SB, Roman, AJ et al. (2012). Gene therapy for leber congenital amaurosis caused by RPE65 mutations: safety and efficacy in 15 children and adults followed up to 3 years. Arch Ophthalmol 130: 9-24.
40. Van Hooser, JP, Aleman, TS, He, YG, Cideciyan, AV, Kuksa, V, Pittler, SJ et al. (2000). Rapid restoration of visual pigment and function with oral retinoid in a mouse model of childhood blindness. Proc Natl Acad Sci USA 97: 8623-8628.
41. Van Hooser, JP, Liang, Y, Maeda, T, Kuksa, V, Jang, GF, He, YG et al. (2002). Recovery of visual functions in a mouse model of Leber congenital amaurosis. J Biol Chem 277: 19173-19182.
42. Roman, AJ, Cideciyan, AV, Aleman, TS and Jacobson, SG (2007). Full-field stimulus testing (FST) to quantify visual perception in severely blind candidates for treatment trials. Physiol Meas 28: N51-N56.
43. Roman, AJ, Schwartz, SB, Aleman, TS, Cideciyan, AV, Chico, JD, Windsor, EA et al. (2005). Quantifying rod photoreceptor-mediated vision in retinal degenerations: darkadapted thresholds as outcome measures. Exp Eye Res 80: 259s-272.
44. Ferris, FL 3rd, Kassoff, A, Bresnick, GH and Bailey, I (1982). New visual acuity charts for clinical research. Am J Ophthalmol 94: 91-96.
45. Fishman, GA, Jacobson, SG, Alexander, KR, Cideciyan, AV, Birch, DG, Weleber, RG et al. (2005). Outcome measures and their application in clinical trials for retinal degenerative diseases: outline, review, and perspective. Retina (Philadelphia, Pa) 25: 772-777.
46. Crossland, MD, Culham, LE, Kabanarou, SA and Rubin, GS (2005). Preferred retinal locus development in patients with macular disease. Ophthalmology 112: 1579-1585.
47. Butz, M, Wörgötter, F and van Ooyen, A (2009). Activity-dependent structural plasticity. Brain Res Rev 60: 287-305.
48. Déruaz, A, Whatham, AR, Mermoud, C and Safran, AB (2002). Reading with multiple preferred retinal loci: implications for training a more efficient reading strategy. Vision Res 42: 2947-2957.
49. Bennett, J, Ashtari, M, Wellman, J, Marshall, KA, Cyckowski, LL, Chung, DC et al. (2012). AAV2 gene therapy readministration in three adults with congenital blindness. Sci Transl Med 4: 120ra15.
50. Mackay, DS, Henderson, RH, Sergouniotis, PI, Li, Z, Moradi, P, Holder, GE et al. (2010). Novel mutations in MERTK associated with childhood onset rod-cone dystrophy. Mol Vis 16: 369-377.
51. Shahzadi, A, Riazuddin, SA, Ali, S, Li, D, Khan, SN, Husnain, T et al. (2010). Nonsense mutation in MERTK causes autosomal recessive retinitis pigmentosa in a consanguineous Pakistani family. Br J Ophthalmol 94: 1094-1099.
52. Ostergaard, E, Duno, M, Batbayli, M, Vilhelmsen, K and Rosenberg, T (2011). A novel MERTK deletion is a common founder mutation in the Faroe Islands and is responsible for a high proportion of retinitis pigmentosa cases. Mol Vis 17: 1485-1492.
53. Bourne, MC, Campbell, DA and Pyke, M (1938). Cataract associated with an hereditary retinal lesion in rats. Br J Ophthalmol 22: 608-613.
54. Bourne, MC, Campbell, DA and Tansley, K (1938). Hereditary degeneration of the rat retina. Br J Ophthalmol 22: 613-623.
55. Dowling, JE and Sidman, RL (1962). Inherited retinal dystrophy in the rat. J Cell Biol 14: 73-109.
56. Herron, WL, Riegel, BW, Myers, OE and Rubin, ML (1969). Retinal dystrophy in the rat-a pigment epithelial disease. Invest Ophthalmol 8: 595-604.
57. LaVail, MM and Battelle, BA (1975). Influence of eye pigmentation and light deprivation on inherited retinal dystrophy in the rat. Exp Eye Res 21: 167-192.
58. LaVail, MM, Sidman, M, Rausin, R and Sidman, RL (1974). Discrimination of light intensity by rats with inherited retinal degeneration: a behavioral and cytological study. Vision Res 14: 693-702.
59. D'Cruz, PM, Yasumura, D, Weir, J, Matthes, MT, Abderrahim, H, LaVail, MM et al. (2000). Mutation of the receptor tyrosine kinase gene Mertk in the retinal dystrophic RCS rat. Hum Mol Genet 9: 645-651.
60. Gal, A, Li, Y, Thompson, DA, Weir, J, Orth, U, Jacobson, SG et al. (2000). Mutations in MERTK, the human orthologue of the RCS rat retinal dystrophy gene, cause retinitis pigmentosa. Nat Genet 26: 270-271.
61. Vollrath, D, Feng, W, Duncan, JL, Yasumura, D, D'Cruz, PM, Chappelow, A et al. (2001). Correction of the retinal dystrophy phenotype of the RCS rat by viral gene transfer of Mertk. Proc Natl Acad Sci USA 98: 12584-12589.
62. Smith, AJ, Schlichtenbrede, FC, Tschernutter, M, Bainbridge, JW, Thrasher, AJ and Ali, RR (2003). AAV-Mediated gene transfer slows photoreceptor loss in the RCS rat model of retinitis pigmentosa. Mol Ther 8: 188-195.
63. Tschernutter, M, Schlichtenbrede, FC, Howe, S, Balaggan, KS, Munro, PM, Bainbridge, JW et al. (2005). Long-term preservation of retinal function in the RCS rat model of retinitis pigmentosa following lentivirus-mediated gene therapy. Gene Ther 12: 694-701.
64. Buch, PK, MacLaren, RE, Durán, Y, Balaggan, KS, MacNeil, A, Schlichtenbrede, FC et al. (2006). In contrast to AAV-mediated Cntf expression, AAV-mediated Gdnf expression enhances gene replacement therapy in rodent models of retinal degeneration. Mol Ther 14: 700-709.
65. Deng, WT, Dinculescu, A, Li, Q, Boye, SL, Li, J, Gorbatyuk, MS et al. (2012). Tyrosinemutant AAV8 delivery of human MERTK provides long-term retinal preservation in RCS rats. Invest Ophthalmol Vis Sci 53: 1895-1904.
66. Vernon, M (1969). Usher's syndrome-deafness and progressive blindness. Clinical cases, prevention, theory and literature survey. J Chronic Dis 22: 133-151.
67. Boughman, JA, Vernon, M and Shaver, KA (1983). Usher syndrome: definition and estimate of prevalence from two high-risk populations. J Chronic Dis 36: 595-603.
68. Petit, C (2001). Usher syndrome: from genetics to pathogenesis. Annu Rev Genomics Hum Genet 2: 271-297.
69. Reiners, J, Nagel-Wolfrum, K, Jürgens, K, Märker, T and Wolfrum, U (2006). Molecular basis of human Usher syndrome: deciphering the meshes of the Usher protein network provides insights into the pathomechanisms of the Usher disease. Exp Eye Res 83: 97-119.
70. Sahly, I, Dufour, E, Schietroma, C, Michel, V, Bahloul, A, Perfettini, I et al. (2012). Localization of Usher 1 proteins to the photoreceptor calyceal processes, which are absent from mice. J Cell Biol 199: 381-399.
71. Weil, D, Blanchard, S, Kaplan, J, Guilford, P, Gibson, F, Walsh, J et al. (1995). Defective myosin VIIA gene responsible for Usher syndrome type 1B. Nature 374: 60-61.
72. Smith, RJ, Berlin, CI, Hejtmancik, JF, Keats, BJ, Kimberling, WJ, Lewis, RA et al. (1994). Clinical diagnosis of the Usher syndromes. Usher Syndrome Consortium. Am J Med Genet 50: 32-38.
73. Hasson, T, Heintzelman, MB, Santos-Sacchi, J, Corey, DP and Mooseker, MS (1995). Expression in cochlea and retina of myosin VIIa, the gene product defective in Usher syndrome type 1B. Proc Natl Acad Sci USA 92: 9815-9819.
74. Weil, D, Levy, G, Sahly, I, Levi-Acobas, F, Blanchard, S, El-Amraoui, A et al. (1996). Human myosin VIIA responsible for the Usher 1B syndrome: a predicted membraneassociated motor protein expressed in developing sensory epithelia. Proc Natl Acad Sci USA 93: 3232-3237.
75. Liu, X, Vansant, G, Udovichenko, IP, Wolfrum, U and Williams, DS (1997). Myosin VIIa, the product of the Usher 1B syndrome gene, is concentrated in the connecting cilia of photoreceptor cells. Cell Motil Cytoskeleton 37: 240-252.
76. Wolfrum, U (2003). The cellular function of the usher gene product myosin VIIa is specified by its ligands. Adv Exp Med Biol 533: 133-142.
77. Liu, X, Ondek, B and Williams, DS (1998). Mutant myosin VIIa causes defective melanosome distribution in the RPE of shaker-1 mice. Nat Genet 19: 117-118.
78. Gibbs, D, Kitamoto, J and Williams, DS (2003). Abnormal phagocytosis by retinal pigmented epithelium that lacks myosin VIIa, the Usher syndrome 1B protein. Proc Natl Acad Sci USA 100: 6481-6486.
79. Gibbs, D, Azarian, SM, Lillo, C, Kitamoto, J, Klomp, AE, Steel, KP et al. (2004). Role of myosin VIIa and Rab27a in the motility and localization of RPE melanosomes. J Cell Sci 117(Pt 26): 6473-6483.
80. Liu, X, Udovichenko, IP, Brown, SD, Steel, KP and Williams, DS (1999). Myosin VIIa participates in opsin transport through the photoreceptor cilium. J Neurosci 19: 6267-6274.
81. Gibbs, D, Diemer, T, Khanobdee, K, Hu, J, Bok, D and Williams, DS (2010). Function of MYO7A in the human RPE and the validity of shaker1 mice as a model for Usher syndrome 1B. Invest Ophthalmol Vis Sci 51: 1130-1135.
82. Hashimoto, T, Gibbs, D, Lillo, C, Azarian, SM, Legacki, E, Zhang, XM et al. (2007). Lentiviral gene replacement therapy of retinas in a mouse model for Usher syndrome type 1B. Gene Ther 14: 584-594.
83. Bainbridge, JW, Stephens, C, Parsley, K, Demaison, C, Halfyard, A, Thrasher, AJ et al. (2001). in vivo gene transfer to the mouse eye using an HIV-based lentiviral vector; efficient long-term transduction of corneal endothelium and retinal pigment epithelium. Gene Ther 8: 1665-1668.
84. Ikeda, Y, Yonemitsu, Y, Miyazaki, M, Kohno, R, Murakami, Y, Murata, T et al. (2009). Stable retinal gene expression in nonhuman primates via subretinal injection of SIVagm-based lentiviral vectors. Hum Gene Ther 20: 573-579.
85. Jacobson, SG, Cideciyan, AV, Aleman, TS, Sumaroka, A, Roman, AJ, Gardner, LM et al. (2008). Usher syndromes due to MYO7A, PCDH15, USH2A or GPR98 mutations share retinal disease mechanism. Hum Mol Genet 17: 2405-2415.
86. Allocca, M, Doria, M, Petrillo, M, Colella, P, Garcia-Hoyos, M, Gibbs, D et al. (2008). Serotype-dependent packaging of large genes in adeno-associated viral vectors results in effective gene delivery in mice. J Clin Invest 118: 1955-1964.
87. Wu, Z, Yang, H and Colosi, P (2010). Effect of genome size on AAV vector packaging. Mol Ther 18: 80-86.
88. Dong, B, Nakai, H and Xiao, W (2010). Characterization of genome integrity for oversized recombinant AAV vector. Mol Ther 18: 87-92.
89. Lai, Y, Yue, Y and Duan, D (2010). Evidence for the failure of adeno-associated virus serotype 5 to package a viral genome > or = 8.2 kb. Mol Ther 18: 75-79.
90. Lopes, VS, Boye, SE, Boye, SL, Hauswirth, WW, Williams, DS. (2010). XIV International Symposium on Retinal Degeneration. Vol. Mont-Tremblant, Quebec, Canada.
91. Lopes, VS, Diemer, T, Gibbs, D, Boye, SE, Boye, SL, Hauswirth, WW and Williams, DS. (2010). XIV International Symposium on Retinal Degeneration. Vol. Mont-Tremblant, Quebec, Canada.
92. Allikmets, R, Shroyer, NF, Singh, N, Seddon, JM, Lewis, RA, Bernstein, PS et al. (1997). Mutation of the Stargardt disease gene (ABCR) in age-related macular degeneration. Science 277: 1805-1807.
93. Quazi, F, Lenevich, S and Molday, RS (2012). ABCA4 is an N-retinylidenephosphatidylethanolamine and phosphatidylethanolamine importer. Nat Commun 3: 925.
94. Molday, RS, Zhong, M and Quazi, F (2009). The role of the photoreceptor ABC transporter ABCA4 in lipid transport and Stargardt macular degeneration. Biochim Biophys Acta 1791: 573-583.
95. Mata, NL, Weng, J and Travis, GH (2000). Biosynthesis of a major lipofuscin fluorophore in mice and humans with ABCR-mediated retinal and macular degeneration. Proc Natl Acad Sci USA 97: 7154-7159.
96. Kong, J, Kim, SR, Binley, K, Pata, I, Doi, K, Mannik, J et al. (2008). Correction of the disease phenotype in the mouse model of Stargardt disease by lentiviral gene therapy. Gene Ther 15: 1311-1320.
97. Han, Z, Conley, SM, Makkia, RS, Cooper, MJ and Naash, MI (2012). DNA nanoparticle-mediated ABCA4 delivery rescues Stargardt dystrophy in mice. J Clin Invest 122: 3221-3226.
98. MacDonald, IM, Mah, DY, Ho, YK, Lewis, RA and Seabra, MC (1998). A practical diagnostic test for choroideremia. Ophthalmology 105: 1637-1640.
99. Cremers, FP, van de Pol, DJ, van Kerkhoff, LP, Wieringa, B and Ropers, HH (1990). Cloning of a gene that is rearranged in patients with choroideraemia. Nature 347: 674-677.
100. Seabra, MC, Brown, MS, Slaughter, CA, Südhof, TC and Goldstein, JL (1992). Purification of component A of Rab geranylgeranyl transferase: possible identity with the choroideremia gene product. Cell 70: 1049-1057.
101. Seabra, MC (1996). New insights into the pathogenesis of choroideremia: a tale of two REPs. Ophthalmic Genet 17: 43-46.
102. Kärnä, J (1986). Choroideremia. A clinical and genetic study of 84 Finnish patients and 126 female carriers. Acta Ophthalmol Suppl 176: 1-68.
103. Sorsby, A, Franceschetti, A, Joseph, R, Davey, JB (1952). Choroideremia; clinical and genetic aspects. Br J Ophthalmol 36: 547-581.
104. Jacobson, SG, Cideciyan, AV, Sumaroka, A, Aleman, TS, Schwartz, SB, Windsor, EA et al. (2006). Remodeling of the human retina in choroideremia: rab escort protein 1 (REP-1) mutations. Invest Ophthalmol Vis Sci 47: 4113-4120.
105. Zerial, M and McBride, H (2001). Rab proteins as membrane organizers. Nat Rev Mol Cell Biol 2: 107-117.
106. Pfeffer, SR (2001). Rab GTPases: specifying and deciphering organelle identity and function. Trends Cell Biol 11: 487-491.
107. Pylypenko, O, Rak, A, Reents, R, Niculae, A, Sidorovitch, V, Cioaca, MD et al. (2003). Structure of Rab escort protein-1 in complex with Rab geranylgeranyltransferase. Mol Cell 11: 483-494.
108. MacDonald, IM, Sereda, C, McTaggart, K and Mah, D (2004). Choroideremia gene testing. Expert Rev Mol Diagn 4: 478-484.
109. Sergeev, YV, Smaoui, N, Sui, R, Stiles, D, Gordiyenko, N, Strunnikova, N et al. (2009). The functional effect of pathogenic mutations in Rab escort protein 1. Mutat Res 665: 44-50.
110. Alory, C and Balch, WE (2001). Organization of the Rab-GDI/CHM superfamily: the functional basis for choroideremia disease. Traffic 2: 532-543.
111. Gordiyenko, NV, Fariss, RN, Zhi, C and MacDonald, IM (2010). Silencing of the CHM gene alters phagocytic and secretory pathways in the retinal pigment epithelium. Invest Ophthalmol Vis Sci 51: 1143-1150.
112. Tolmachova, T, Anders, R, Abrink, M, Bugeon, L, Dallman, MJ, Futter, CE et al. (2006). Independent degeneration of photoreceptors and retinal pigment epithelium in conditional knockout mouse models of choroideremia. J Clin Invest 116: 386-394.
113. Tolmachova, T, Wavre-Shapton, ST, Barnard, AR, MacLaren, RE, Futter, CE and Seabra, MC (2010). Retinal pigment epithelium defects accelerate photoreceptor degeneration in cell type-specific knockout mouse models of choroideremia. Invest Ophthalmol Vis Sci 51: 4913-4920.
114. Anand, V, Barral, DC, Zeng, Y, Brunsmann, F, Maguire, AM, Seabra, MC et al. (2003). Gene therapy for choroideremia: in vitro rescue mediated by recombinant adenovirus. Vision Res 43: 919-926.
115. Tolmachova, T, Tolmachov, OE, Wavre-Shapton, ST, Tracey-White, D, Futter, CE and Seabra, MC (2012). CHM/REP1 cDNA delivery by lentiviral vectors provides functional expression of the transgene in the retinal pigment epithelium of choroideremia mice. J Gene Med 14: 158-168.
116. MacLaren, RE, Groppe, M, Barnard, AR, Tolmachova, T, During, MJ, Downes, SM et al (2012). Association for Research in Vision and Opthalmology (ARVO), Ft. Lauderdale, FL.
117. Adamis, AP, Miller, JW, Bernal, MT, D'Amico, DJ, Folkman, J, Yeo, TK et al. (1994). Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 118: 445-450.
118. Kvanta, A, Algvere, PV, Berglin, L and Seregard, S (1996). Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest Ophthalmol Vis Sci 37: 1929-1934.
119. Aiello, LP, Pierce, EA, Foley, ED, Takagi, H, Chen, H, Riddle, L et al. (1995). Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci USA 92: 10457-10461.
120. Brown, DM and Regillo, CD (2007). Anti-VEGF agents in the treatment of neovascular age-related macular degeneration: applying clinical trial results to the treatment of everyday patients. Am J Ophthalmol 144: 627-637.
121. Rosenfeld, PJ, Rich, RM and Lalwani, GA (2006). Ranibizumab: Phase III clinical trial results. Ophthalmol Clin North Am 19: 361-372.
122. D'Amico, DJ, Masonson, HN, Patel, M, Adamis, AP, Cunningham, ET, Jr, Guyer, DR et al (2006). Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology 113: 992-1001.
123. Lai, YK, Shen, WY, Brankov, M, Lai, CM, Constable, IJ and Rakoczy, PE (2002). Potential long-term inhibition of ocular neovascularisation by recombinant adenoassociated virus-mediated secretion gene therapy. Gene Ther 9: 804-813.
124. Lai, CM, Shen, WY, Brankov, M, Lai, YK, Barnett, NL, Lee, SY et al. (2005). Long-term evaluation of AAV-mediated sFlt-1 gene therapy for ocular neovascularization in mice and monkeys. Mol Ther 12: 659-668.
125. Lai, CM, Estcourt, MJ, Himbeck, RP, Lee, SY, Yew-San Yeo, I, Luu, C et al. (2012). Preclinical safety evaluation of subretinal AAV2.sFlt-1 in non-human primates. Gene Ther 19: 999-1009.
126. Pechan, P, Rubin, H, Lukason, M, Ardinger, J, DuFresne, E, Hauswirth, WW et al. (2009). Novel anti-VEGF chimeric molecules delivered by AAV vectors for inhibition of retinal neovascularization. Gene Ther 16: 10-16.
127. Lai, CM, Estcourt, MJ, Wikstrom, M, Himbeck, RP, Barnett, NL, Brankov, M et al. (2009). rAAV.sFlt-1 gene therapy achieves lasting reversal of retinal neovascularization in the absence of a strong immune response to the viral vector. Invest Ophthalmol Vis Sci 50: 4279-4287.
128. Lukason, M, DuFresne, E, Rubin, H, Pechan, P, Li, Q, Kim, I et al. (2011). Inhibition of choroidal neovascularization in a nonhuman primate model by intravitreal administration of an AAV2 vector expressing a novel anti-VEGF molecule. Mol Ther 19: 260-265.
129. Igarashi, T, Miyake, K, Masuda, I, Takahashi, H and Shimada, T (2010). Adenoassociated vector (type 8)-mediated expression of soluble Flt-1 efficiently inhibits neovascularization in a murine choroidal neovascularization model. Hum Gene Ther 21: 631-637.
130. Maclachlan, TK, Lukason, M, Collins, M, Munger, R, Isenberger, E, Rogers, C et al. (2011). Preclinical safety evaluation of AAV2-sFLT01- a gene therapy for age-related macular degeneration. Mol Ther 19: 326-334.
131. O'Reilly, MS, Boehm, T, Shing, Y, Fukai, N, Vasios, G, Lane, WS et al. (1997). Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88: 277-285.
132. O'Reilly, MS (1997). Angiostatin: an endogenous inhibitor of angiogenesis and of tumor growth. EXS 79: 273-294.
133. Mori, K, Ando, A, Gehlbach, P, Nesbitt, D, Takahashi, K, Goldsteen, D et al. (2001). Inhibition of choroidal neovascularization by intravenous injection of adenoviral vectors expressing secretable endostatin. Am J Pathol 159: 313-320.
134. Lai, LJ, Xiao, X and Wu, JH (2007). Inhibition of corneal neovascularization with endostatin delivered by adeno-associated viral (AAV) vector in a mouse corneal injury model. J Biomed Sci 14: 313-322.
135. Raisler, BJ, Berns, KI, Grant, MB, Beliaev, D and Hauswirth, WW (2002). Adenoassociated virus type-2 expression of pigmented epithelium-derived factor or Kringles 1-3 of angiostatin reduce retinal neovascularization. Proc Natl Acad Sci USA 99: 8909-8914.
136. Igarashi, T, Miyake, K, Kato, K, Watanabe, A, Ishizaki, M, Ohara, K et al. (2003). Lentivirus-mediated expression of angiostatin efficiently inhibits neovascularization in a murine proliferative retinopathy model. Gene Ther 10: 219-226.
137. den Hollander, AI, Roepman, R, Koenekoop, RK and Cremers, FP (2008). Leber congenital amaurosis: genes, proteins and disease mechanisms. Prog Retin Eye Res 27: 391-419.
138. Milam, AH, Barakat, MR, Gupta, N, Rose, L, Aleman, TS, Pianta, MJ et al. (2003). Clinicopathologic effects of mutant GUCY2D in Leber congenital amaurosis. Ophthalmology 110: 549-558.
139. Perrault, I, Rozet, JM, Gerber, S, Ghazi, I, Ducroq, D, Souied, E et al. (2000). Spectrum of retGC1 mutations in Leber's congenital amaurosis. Eur J Hum Genet 8: 578-582.
140. Li, L, Xiao, X, Li, S, Jia, X, Wang, P, Guo, X et al. (2011). Detection of variants in 15 genes in 87 unrelated Chinese patients with Leber congenital amaurosis. PLoS ONE 6: e19458.
141. Dizhoor, AM, Lowe, DG, Olshevskaya, EV, Laura, RP and Hurley, JB (1994). The human photoreceptor membrane guanylyl cyclase, RetGC, is present in outer segments and is regulated by calcium and a soluble activator. Neuron 12: 1345-1352.
142. Liu, X, Seno, K, Nishizawa, Y, Hayashi, F, Yamazaki, A, Matsumoto, H et al. (1994). Ultrastructural localization of retinal guanylate cyclase in human and monkey retinas. Exp Eye Res 59: 761-768.
143. 2+! The physiology and pathology of Ca(2+)-binding proteins in the retina. Trends Neurosci 19: 547-554.
144. Yang, RB and Garbers, DL (1997). Two eye guanylyl cyclases are expressed in the same photoreceptor cells and form homomers in preference to heteromers. J Biol Chem 272: 13738-13742.
145. Karan, S, Frederick, JM and Baehr, W (2010). Novel functions of photoreceptor guanylate cyclases revealed by targeted deletion. Mol Cell Biochem 334: 141-155.
146. Jacobson, SG, Cideciyan, AV, Peshenko, IV, Sumaroka, A, Olshevskaya, EV, Cao, L et al. (2013). Determining consequences of retinal membrane guanylyl cyclase (RetGC1) deficiency in human Leber congenital amaurosis en route to therapy: residual conephotoreceptor vision correlates with biochemical properties of the mutants. Hum Mol Genet 22: 168-183.
147. Pasadhika, S, Fishman, GA, Stone, EM, Lindeman, M, Zelkha, R, Lopez, I et al. (2010). Differential macular morphology in patients with RPE65-, CEP290-, GUCY2D-, and AIPL1-related Leber congenital amaurosis. Invest Ophthalmol Vis Sci 51: 2608-2614.
148. Simonelli, F, Ziviello, C, Testa, F, Rossi, S, Fazzi, E, Bianchi, PE et al. (2007). Clinical and molecular genetics of Leber's congenital amaurosis: a multicenter study of Italian patients. Invest Ophthalmol Vis Sci 48: 4284-4290.
149. Yang, RB, Robinson, SW, Xiong, WH, Yau, KW, Birch, DG and Garbers, DL (1999). Disruption of a retinal guanylyl cyclase gene leads to cone-specific dystrophy and paradoxical rod behavior. J Neurosci 19: 5889-5897.
150. Boye, SE, Boye, SL, Pang, J, Ryals, R, Everhart, D, Umino, Y et al. (2010). Functional and behavioral restoration of vision by gene therapy in the guanylate cyclase-1 (GC1) knockout mouse. PLoS ONE 5: e11306.
151. Boye, SL, Conlon, T, Erger, K, Ryals, R, Neeley, A, Cossette, T et al. (2011). Long-term preservation of cone photoreceptors and restoration of cone function by gene therapy in the guanylate cyclase-1 knockout (GC1KO) mouse. Invest Ophthalmol Vis Sci 52: 7098-7108.
152. Mihelec, M, Pearson, RA, Robbie, SJ, Buch, PK, Azam, SA, Bainbridge, JW et al. (2011). Long-term preservation of cones and improvement in visual function following gene therapy in a mouse model of leber congenital amaurosis caused by guanylate cyclase-1 deficiency. Hum Gene Ther 22: 1179-1190.
153. Baehr, W, Karan, S, Maeda, T, Luo, DG, Li, S, Bronson, JD et al. (2007). The function of guanylate cyclase 1 and guanylate cyclase 2 in rod and cone photoreceptors. J Biol Chem 282: 8837-8847.
154. Boye, SL, Peshenko, IV, Huang, WC, Min, SH, McDoom, I, Kay, CN et al. (2012). AAVmediated gene therapy in the guanylate cyclase (RetGC1/RetGC2) double knockout mouse model of Leber congenital amaurosis. Hum Gene Ther (epub ahead of print).
155. Boye, SE, Alexander, JJ, Boye, SL, Witherspoon, CD, Sandefer, KJ, Conlon, TJ et al. (2012). The human rhodopsin kinase promoter in an AAV5 vector confers rod- and cone-specific expression in the primate retina. Hum Gene Ther 23: 1101-1115.
156. Thiadens, AA, Somervuo, V, van den Born, LI, Roosing, S, van Schooneveld, MJ, Kuijpers, RW et al. (2010). Progressive loss of cones in achromatopsia: an imaging study using spectral-domain optical coherence tomography. Invest Ophthalmol Vis Sci 51: 5952-5957.
157. Kohl, S, Marx, T, Giddings, I, Jägle, H, Jacobson, SG, Apfelstedt-Sylla, E et al. (1998). Total colourblindness is caused by mutations in the gene encoding the alpha-subunit of the cone photoreceptor cGMP-gated cation channel. Nat Genet 19: 257-259.
158. Kohl, S, Baumann, B, Broghammer, M, Jägle, H, Sieving, P, Kellner, U et al. (2000). Mutations in the CNGB3 gene encoding the beta-subunit of the cone photoreceptor cGMP-gated channel are responsible for achromatopsia (ACHM3) linked to chromosome 8q21. Hum Mol Genet 9: 2107-2116.
159. Aligianis, IA, Forshew, T, Johnson, S, Michaelides, M, Johnson, CA, Trembath, RC et al. (2002). Mapping of a novel locus for achromatopsia (ACHM4) to 1p and identification of a germline mutation in the alpha subunit of cone transducin (GNAT2). J Med Genet 39: 656-660.
160. Kohl, S, Baumann, B, Rosenberg, T, Kellner, U, Lorenz, B, Vadalà, M et al. (2002). Mutations in the cone photoreceptor G-protein alpha-subunit gene GNAT2 in patients with achromatopsia. Am J Hum Genet 71: 422-425.
161. Thiadens, AA, den Hollander, AI, Roosing, S, Nabuurs, SB, Zekveld-Vroon, RC, Collin, RW et al. (2009). Homozygosity mapping reveals PDE6C mutations in patients with early-onset cone photoreceptor disorders. Am J Hum Genet 85: 240-247.
162. Alexander, JJ, Umino, Y, Everhart, D, Chang, B, Min, SH, Li, Q et al. (2007). Restoration of cone vision in a mouse model of achromatopsia. Nat Med 13: 685-687.
163. Chang, B, Dacey, MS, Hawes, NL, Hitchcock, PF, Milam, AH, Atmaca-Sonmez, P et al. (2006). Cone photoreceptor function loss-3, a novel mouse model of achromatopsia due to a mutation in Gnat2. Invest Ophthalmol Vis Sci 47: 5017-5021.
164. Komáromy, AM, Alexander, JJ, Rowlan, JS, Garcia, MM, Chiodo, VA, Kaya, A et al. (2010). Gene therapy rescues cone function in congenital achromatopsia. Hum Mol Genet 19: 2581-2593.
165. Michalakis, S, Mühlfriedel, R, Tanimoto, N, Krishnamoorthy, V, Koch, S, Fischer, MD et al. (2010). Restoration of cone vision in the CNGA3-/- mouse model of congenital complete lack of cone photoreceptor function. Mol Ther 18: 2057-2063.
166. Carvalho, LS, Xu, J, Pearson, RA, Smith, AJ, Bainbridge, JW, Morris, LM et al. (2011). Long-term and age-dependent restoration of visual function in a mouse model of CNGB3- associated achromatopsia following gene therapy. Hum Mol Genet 20: 3161-3175.
167. Pang, JJ, Deng, WT, Dai, X, Lei, B, Everhart, D, Umino, Y et al. (2012). AAV-mediated cone rescue in a naturally occurring mouse model of CNGA3-achromatopsia. PLoS ONE 7: e35250.
168. George, ND, Yates, JR and Moore, AT (1995). X linked retinoschisis. Br J Ophthalmol 79: 697-702.
169. Prenner, JL, Capone, A Jr, Ciaccia, S, Takada, Y, Sieving, PA and Trese, MT (2006). Congenital X-linked retinoschisis classification system. Retina (Philadelphia, Pa) 26(suppl. 7): S61-S64.
170. Minami, Y, Ishiko, S, Takai, Y, Kato, Y, Kagokawa, H, Takamiya, A et al. (2005). Retinal changes in juvenile X linked retinoschisis using three dimensional optical coherence tomography. Br J Ophthalmol 89: 1663-1664.
171. Peachey, NS, Fishman, GA, Derlacki, DJ and Brigell, MG (1987). Psychophysical and electroretinographic findings in X-linked juvenile retinoschisis. Arch Ophthalmol 105: 513-516.
172. Roesch, MT, Ewing, CC, Gibson, AE and Weber, BH (1998). The natural history of X-linked retinoschisis. Can J Ophthalmol 33: 149-158.
173. Sauer, CG, Gehrig, A, Warneke-Wittstock, R, Marquardt, A, Ewing, CC, Gibson, A et al. (1997). Positional cloning of the gene associated with X-linked juvenile retinoschisis. Nat Genet 17: 164-170.
174. Takada, Y, Fariss, RN, Muller, M, Bush, RA, Rushing, EJ and Sieving, PA (2006). Retinoschisin expression and localization in rodent and human pineal and consequences of mouse RS1 gene knockout. Mol Vis 12: 1108-1116.
175. Wu, WW, Wong, JP, Kast, J and Molday, RS (2005). RS1, a discoidin domain-containing retinal cell adhesion protein associated with X-linked retinoschisis, exists as a novel disulfide-linked octamer. J Biol Chem 280: 10721-10730.
176. Baumgartner, S, Hofmann, K, Chiquet-Ehrismann, R and Bucher, P (1998). The discoidin domain family revisited: new members from prokaryotes and a homologybased fold prediction. Protein Sci 7: 1626-1631.
177. Zeng, Y, Takada, Y, Kjellstrom, S, Hiriyanna, K, Tanikawa, A, Wawrousek, E et al. (2004). RS-1 Gene Delivery to an Adult Rs1h Knockout Mouse Model Restores ERG b-Wave with Reversal of the Electronegative Waveform of X-Linked Retinoschisis. Invest Ophthalmol Vis Sci 45: 3279-3285.
178. Weber, BH, Schrewe, H, Molday, LL, Gehrig, A, White, KL, Seeliger, MW et al. (2002). Inactivation of the murine X-linked juvenile retinoschisis gene, Rs1h, suggests a role of retinoschisin in retinal cell layer organization and synaptic structure. Proc Natl Acad Sci USA 99: 6222-6227.
179. Kjellstrom, S, Bush, RA, Zeng, Y, Takada, Y and Sieving, PA (2007). Retinoschisin gene therapy and natural history in the Rs1h-KO mouse: long-term rescue from retinal degeneration. Invest Ophthalmol Vis Sci 48: 3837-3845.
180. Min, SH, Molday, LL, Seeliger, MW, Dinculescu, A, Timmers, AM, Janssen, A et al. (2005). Prolonged recovery of retinal structure/function after gene therapy in an Rs1h-deficient mouse model of x-linked juvenile retinoschisis. Mol Ther 12: 644-651.
181. Janssen, A, Min, SH, Molday, LL, Tanimoto, N, Seeliger, MW, Hauswirth, WW et al. (2008). Effect of late-stage therapy on disease progression in AAV-mediated rescue of photoreceptor cells in the retinoschisin-deficient mouse. Mol Ther 16: 1010-1017.
182. Takada, Y, Vijayasarathy, C, Zeng, Y, Kjellstrom, S, Bush, RA and Sieving, PA (2008). Synaptic pathology in retinoschisis knockout (Rs1-/y) mouse retina and modification by rAAV-Rs1 gene delivery. Invest Ophthalmol Vis Sci 49: 3677-3686.
183. Park, TK, Wu, Z, Kjellstrom, S, Zeng, Y, Bush, RA, Sieving, PA et al. (2009). Intravitreal delivery of AAV8 retinoschisin results in cell type-specific gene expression and retinal rescue in the Rs1-KO mouse. Gene Ther 16: 916-926.
184. Grayson, C and Molday, RS (2005). Dominant negative mechanism underlies autosomal dominant Stargardt-like macular dystrophy linked to mutations in ELOVL4. J Biol Chem 280: 32521-32530.
185. Sung, CH, Makino, C, Baylor, D and Nathans, J (1994). A rhodopsin gene mutation responsible for autosomal dominant retinitis pigmentosa results in a protein that is defective in localization to the photoreceptor outer segment. J Neurosci 14: 5818-5833.
186. Cai, X, Conley, SM, Nash, Z, Fliesler, SJ, Cooper, MJ and Naash, MI (2010). Gene delivery to mitotic and postmitotic photoreceptors via compacted DNA nanoparticles results in improved phenotype in a mouse model of retinitis pigmentosa. FASEB J 24: 1178-1191.
187. LaVail, MM, Yasumura, D, Matthes, MT, Drenser, KA, Flannery, JG, Lewin, AS et al. (2000). Ribozyme rescue of photoreceptor cells in P23H transgenic rats: long-term survival and late-stage therapy. Proc Natl Acad Sci USA 97: 11488-11493.
188. Lewin, AS, Drenser, KA, Hauswirth, WW, Nishikawa, S, Yasumura, D, Flannery, JG et al. (1998). Ribozyme rescue of photoreceptor cells in a transgenic rat model of autosomal dominant retinitis pigmentosa. Nat Med 4: 967-971.
189. Millington-Ward, S, O'Neill, B, Tuohy, G, Al-Jandal, N, Kiang, AS, Kenna, PF et al. (1997). Strategems in vitro for gene therapies directed to dominant mutations. Hum Mol Genet 6: 1415-1426.
190. Chadderton, N, Millington-Ward, S, Palfi, A, O'Reilly, M, Tuohy, G, Humphries, MM et al. (2009). Improved retinal function in a mouse model of dominant retinitis pigmentosa following AAV-delivered gene therapy. Mol Ther 17: 593-599.
191. Georgiadis, A, Tschernutter, M, Bainbridge, JW, Robbie, SJ, McIntosh, J, Nathwani, AC et al. (2010). AAV-mediated knockdown of peripherin-2 in vivo using miRNA-based hairpins. Gene Ther 17: 486-493.
192. Gorbatyuk, M, Justilien, V, Liu, J, Hauswirth, WW and Lewin, AS (2007). Preservation of photoreceptor morphology and function in P23H rats using an allele independent ribozyme. Exp Eye Res 84: 44-52.
193. Gorbatyuk, MS, Pang, JJ, Thomas, J Jr, Hauswirth, WW and Lewin, AS (2005). Knockdown of wild-type mouse rhodopsin using an AAV vectored ribozyme as part of an RNA replacement approach. Mol Vis 11: 648-656.
194. Millington-Ward, S, Chadderton, N, O'Reilly, M, Palfi, A, Goldmann, T, Kilty, C et al. (2011). Suppression and replacement gene therapy for autosomal dominant disease in a murine model of dominant retinitis pigmentosa. Mol Ther 19: 642-649.
195. O'Reilly, M, Palfi, A, Chadderton, N, Millington-Ward, S, Ader, M, Cronin, T et al. (2007). RNA interference-mediated suppression and replacement of human rhodopsin in vivo. Am J Hum Genet 81: 127-135.
196. Sullivan, JM, Pietras, KM, Shin, BJ and Misasi, JN (2002). Hammerhead ribozymes designed to cleave all human rod opsin mRNAs which cause autosomal dominant retinitis pigmentosa. Mol Vis 8: 102-113.
197. Palfi, A, Millington-Ward, S, Chadderton, N, O'Reilly, M, Goldmann, T, Humphries, MM et al. (2010). Adeno-associated virus-mediated rhodopsin replacement provides therapeutic benefit in mice with a targeted disruption of the rhodopsin gene. Hum Gene Ther 21: 311-323.
198. Mao, H, Gorbatyuk, MS, Rossmiller, B, Hauswirth, WW and Lewin, AS (2012). Longterm rescue of retinal structure and function by rhodopsin RNA replacement with a single adeno-associated viral vector in P23H RHO transgenic mice. Hum Gene Ther 23: 356-366.
199. Mussolino, C, Sanges, D, Marrocco, E, Bonetti, C, Di Vicino, U, Marigo, V et al. (2011). Zinc-finger-based transcriptional repression of rhodopsin in a model of dominant retinitis pigmentosa. EMBO Mol Med 3: 118-128.
200. Mao, H, James, T Jr, Schwein, A, Shabashvili, AE, Hauswirth, WW, Gorbatyuk, MS et al. (2011). AAV delivery of wild-type rhodopsin preserves retinal function in a mouse model of autosomal dominant retinitis pigmentosa. Hum Gene Ther 22: 567-575.
201. Gorbatyuk, MS, Knox, T, LaVail, MM, Gorbatyuk, OS, Noorwez, SM, Hauswirth, WW et al. (2010). Restoration of visual function in P23H rhodopsin transgenic rats by gene delivery of BiP/Grp78. Proc Natl Acad Sci USA 107: 5961-5966.
202. Wallace, DC, Singh, G, Lott, MT, Hodge, JA, Schurr, TG, Lezza, AM et al. (1988). Mitochondrial DNA mutation associated with Leber's hereditary optic neuropathy. Science 242: 1427-1430.
203. Yu, H, Koilkonda, RD, Chou, TH, Porciatti, V, Ozdemir, SS, Chiodo, V et al. (2012). Gene delivery to mitochondria by targeting modified adenoassociated virus suppresses Leber's hereditary optic neuropathy in a mouse model. Proc Natl Acad Sci USA 109: E1238-E1247.
204. Glick, B and Schatz, G (1991). Import of proteins into mitochondria. Annu Rev Genet 25: 21-44.
205. Neupert, W (1997). Protein import into mitochondria. Annu Rev Biochem 66: 863-917.
206. Qi, X, Sun, L, Lewin, AS, Hauswirth, WW and Guy, J (2007). The mutant human ND4 subunit of complex I induces optic neuropathy in the mouse. Invest Ophthalmol Vis Sci 48: 1-10.
207. Ellouze, S, Augustin, S, Bouaita, A, Bonnet, C, Simonutti, M, Forster, V et al. (2008). Optimized allotopic expression of the human mitochondrial ND4 prevents blindness in a rat model of mitochondrial dysfunction. Am J Hum Genet 83: 373-387.
208. Guy, J, Qi, X, Koilkonda, RD, Arguello, T, Chou, TH, Ruggeri, M et al. (2009). Efficiency and safety of AAV-mediated gene delivery of the human ND4 complex I subunit in the mouse visual system. Invest Ophthalmol Vis Sci 50: 4205-4214.